



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated February 05, 2020

To,
National Stock Exchange of India Limited,
BSE Limited
Symbol: GRANULES Scrip Code: 532482

Sub: Granules Pharmaceuticals, Inc. received US FDA approval for Valganciclovir Hydrochloride for Oral Solution

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc., a wholly owned foreign subsidiary of Granules India Limited for Valganciclovir Hydrochloride for Oral Solution, 50 mg/mL. It is bioequivalent to the reference listed drug product (RLD), Valcyte for Oral Solution, 50 mg/mL, of Roche Palo Alto LLC.

Valganciclovir Hydrochloride solution is an antiviral medication used to treat cytomegalovirus infections.

This is for your information and dissemination to the members

Thanking you.

Yours faithfully

FOR GRANULES INDIA LIMITED

G. Chaitanya

**CHAITANYA TUMMALA
COMPANY SECRETARY
COMPLIANCE OFFICER**

